Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) Q4 2019 Earnings Conference Call February 20, 2020 4:30 PM ET

Company Participants

Vincent Perrone - Director, Corporate Communications
Steven Shallcross - Chief Executive Officer and Chief Financial Officer
Vince Wacher - Head of Product and Corporate Development

Conference Call Participants

Michael Okunewitch - Maxim Group

Operator

Good afternoon and welcome to Synthetic Biologics' 2019 Year End Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.

At this time, I would like to turn the call over to Vincent Perrone, Director, Corporate Communications at Synthetic Biologics. Vincent?

Vincent Perrone

Thank you, Carrie and good afternoon everyone. Welcome to Synthetic Biologics' 2019 year end investor conference call. Today, I am joined by our Chief Executive and Financial Officer, Steven Shallcross; Dr. Michael Kaleko, SVP of Research and Development; and Dr. Vince Wacher, Head of Product and Corporate Development.

Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the year ending December 31, 2019. The release can be found in the Investor section of our website.

During our call today, we'll provide an operational update on our GI and microbiome-focused clinical programs and will summarize our financial results. We'll take questions after prepared our remarks. In addition to the phone line, this call is being streamed live via webcast, which will be archived on our website, www.syntheticbiologics.com for 90 days.

During this call, we will be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminologies such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, including those set forth in Synthetic Biologics' filings with the SEC, many of which are difficult